Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 15, 2012

166_ip_2012-05-15_b0258386-36e1-42a8-91da-76e611112747.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Deutsche BankGerman & Austrian Corporate Conference

May 15, 2012

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results

Sales 5-year CAGR: 10%

EBIT5-year CAGR: 12%

Net Income5-year CAGR: 17%

Group financial results before APP-transaction-related special items

Fresenius Share: Attractive Long-Term Shareholder Returns

Source: Bloomberg; dividends reinvested 1 Proposal

Fresenius Group: Financial Results

1
S
l
a
e
s		 E
B
I
T		 2
N
i
t
e
n
c
o
m
e
/
Q
1
1
2		 €
9
4
4
1
m
,		 €
6
6
1
m		 €
2
0
0
m
G
h
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 1
0
%		 1
2
%		 1
5
%
h
l
G
t
t
t
r
o
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 3
%
1		 1
%
5		 1
8
%

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

2Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain at Fresenius Medical Care

Fresenius Group: Financial Results by Business Segment

/
Q
1
1
2		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
l
S
a
e
s
h
G
t
o
r
w		 \$
S
3
2
9
U
4
m
,
9
%		 €
1
0
9
2
m
,
1
4
%		 €
7
1
7
m
1
1
%		 €
1
4
2
m
1
%
E
B
I
T
h
G
t
o
r
w		 \$
S
0
3
U
5
m
1
3
%		 €
2
1
5
m
9
%		 €
6
8
m
1
7
%		 €
5
m
0
%

Fresenius Kabi: Update Q1/12

  • 11% organic sales growth, all regions at or above expectations
  • North America strong growth continues due to 2011 launches (e.g. PipTazo, Nafcillin) and persisting drug shortages
  • 16% organic sales growth in I.V. drugs outside North America, 14% organic sales growth in Clinical Nutrition
  • Raised 2012 outlook reflects excellent Q1 results and current drug shortage expectations for Q2

Strong Organic Growth in All Regions

Fresenius Helios: Update Q1/12

    • 5% organic sales growth – at upper end of guidance, 4% increase in admissions
    • Excellent margin development across all hospitals in established business – 170 bps EBIT margin increase to 10.7%
    • Damp acquisition consolidated as of March 31, 2012
    • Excellent supply cost management – 2009-2011: 140 bps decrease to 19.0% in supply costs as percentage of sales

Fresenius Vamed: Update Q1/12

  • -Sales and EBIT in line with expectations
    • 16% sales growth in service business – broad portfolio of ~150 multi-year service contracts supports long-term growth
    • Order intake in project business particularly strong in Emerging Markets
  • €63 million turnkey project in the Ukraine
  • €13 million additional medical equipment contracts in China
  • -Fully confirm 2012 outlook

Fresenius Group: Financial Outlook by Business Segment Fully Confirmed or Raised

i
P
r
e
v
o
u
s		 N
e
w
F
i
r
e
s
e
n
u
s
K
b
i
a		 1
l
h
S
t
a
e
s
g
r
o
w
E
B
I
T
i
m
a
g
n
r		 4
%
6
%
–
1
9
5
%
2
0
%
–		 8
6
%
%
–
d
f
p
p
e
e
n
o
a
n
g
e
u
r
r
i
F
r
e
s
e
n
u
s
H
l
i
e
o
s		 1
l
h
S
t
a
e
s
g
o
r
w
E
B
I
T		 3
%
5
%
–
€
3
0
€
3
2
0
1
m
m
–		 f
d
i
c
o
n
m
e
r
f
d
u
p
p
e
r
e
n
o
r
a
n
g
e
F
i
r
e
s
e
n
s
u
d
V
a
m
e		 S
l
h
t
a
e
s
g
r
o
w
h
E
B
I
T
t
g
o
r
w		 %
0
%
5
1
–
5
%
1
0
%
–		 f
d
i
c
o
n
r
m
e
f
d
i
c
o
n
m
e
r
i
F
r
e
s
e
n
u
s
B
i
h
t
o
e
c		 E
B
I
T		 €
2
5
€
3
0
m
m
~
-
–
-		 f
d
i
c
o
n
m
e
r

1 organic

Fresenius Group: Financial Outlook Raised

P
i
r
e
v
o
u
s		 N
e
w
1
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 1
0
%
1
3
%
–		 d
f
u
p
p
e
r
e
n
o
r
a
n
g
e
2
h
N
i
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 8
%
1
1
%
–		 1
2
%
1
5
%
–
C
a
p
e
x		 f
l
%
G
5
o
o
p
s
a
e
s
r
u
~		 f
d
i
c
o
n
m
e
r

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain at Fresenius Medical Care Outlook before effects of the announced Rhön-Klinikum AG acquisition

Attachments

Fresenius Group: Profit and Loss Statement

€
m		 Q
/
1
1
2		 Q
/
1
1
1		 G
h
Q
t
r
o
w		 /
1
1
2
Y
Y
o
l
t
a
c
u
a
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s
1
l
S
a
e
s		 9
4
4
1
,		 3
9
2
3
,		 1
3
%		 1
0
%
E
B
I
T		 6
6
1		 5
7
5		 1
5
%		 1
2
%
N
i
t
t
t
e
n
e
e
r
s		 1
4
7
-		 3
1
5
-		 9
%
-		 6
%
-
I
t
n
c
o
m
e
a
e
s
x		 1
5
6
-		 1
3
5
-		 1
6
%
-		 1
3
%
-
2
N
i
t
e
n
c
o
m
e		 2
0
0		 1
7
0		 8
1
%		 1
5
%

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain at Fresenius Medical Care, 2011 before special items due to MEB and CVR accounting

Fresenius Group: Cash Flow

€
m		 /
Q
2
1
1		 L
T
M
1
M
i
a
r
g
n		 /
Q
1
1
1		 L
T
M
1
M
i
a
r
g
n		 G
h
t
r
o
w
Y
Y
o
O
i
C
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 3
8
5		 1
1
6
%		 2
7
8		 1
0
8
%		 9
4
%
C
(
)
t
a
p
e
x
n
e		 1
2
5
-		 4
6
%
-		 1
4
7
-		 4
6
%
-		 3
%
-
C
h
l
F
F
r
e
e
a
s
o
w
(
b
f
d
d
d
d
)
i
i
i
i
i
t
e
o
e
a
q
s
o
n
s
a
n
e
n
s
r
c
u
v		 3
8
6		 7
0
%		 1
3
1		 6
2
%		 1
9
5
%
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 8
1,
4
5
-		 2
9
4
-		 --
d
d
D
i
i
v
e
n
s		 2
4
-		 1
5
-		 6
0
%
-
F
C
h
F
l
r
e
e
a
s
o
w
(
f
i
i
i
d
d
i
i
d
d
)
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 0
9
1
6
-
,		 1
0
2
%
-		 1
3
3
-		 -- --

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Cash Flow Development

€
m		 O
p
e
r
a		 (
)
i
C
F
C
F
C
h
F
l
t
t
n
g
a
p
e
n
e
r
e
e
a
s
o
x		 1
w
Q
/
2
1
1		 L
T
M
M
i
a
r
g
n		 Q
/
2
1
1		 L
T
M
M
i
a
r
g
n		 Q
/
2
1
1		 L
T
M
M
i
a
r
g
n
9
3		 9
%
1
1		 (
3
6
)		 (
0
%
)
4		 5
7		 9
%
7
3
4		 9
5
%		 (
)
1
9		 (
)
5
8
%		 1
5		 3
3
7
%
4
5		 8
7
%
-		 (
)
1		 (
0
8
)
%		 4
4		 9
5
%
-
Co
/
te
rp
or
a
O
he
t
r		 1
-		 /
n
a		 (
)
3		 /
n
a		 4
-		 /
n
a
l.
F
M
C
ex
c		 1
7
1		 9
6
%
2		 (
)
5
9		 (
)
4
5
%		 1
1
2		 2
5
1
%
Gr
ou
p		 5
3
8		 %
1
1
6		 (
)
1
5
2		 (
)
%
4
6		 8
3
6		 %
7
0

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 5.4% excluding €45 million of capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

M
3
1
a
r
,
2
0
1
2		 D
3
1
e
c
,
2
0
1
1
b
(
)
D
€
t
e
m
\$
he
f
5
4
%
U
S
t
re
o
de
in
d
te
no
m
a		 1
1
4
5
9
,		 9
7
9
9
,
d
b
(
)
N
€
t
t
e
e
m		 1
0
6
0
4
,		 9
1
6
4
,
d
b
/
N
E
B
I
T
D
A
t
t
e
e		 1
3
0
1		 2
8
3
/
E
B
I
T
D
A
I
t
t
n
e
e
s
r		 5
7		 6
1

Net debt/EBITDA

1Pro forma Liberty Dialysis Holdings, Inc. and Damp Group from Q1 2012

2Before effects of the announced Rhön-Klinikum AG acquisition

Debt excludes Mandatory Exchangeable Bonds which came to maturity on August 14, 2011

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
1
1
2		 Q
/
1
1
1		 O
i
r
g
a
n
c
G
h
t
r
o
w
f
h
I
i
T
n
u
s
o
n
e
r
a
p
y		 2
4
6		 2
2
0		 1
0
%
I.
V
D
g
s
r
u		 4
1
0		 3
5
5		 1
2
%
l
l
C
i
i
N
i
i
t
t
n
c
a
u
r
o
n		 3
1
6		 2
7
0		 1
4
%
d
l
/
M
i
D
i
e
c
a
e
v
c
e
s
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 1
2
0		 1
1
5		 4
%
T
l
l
t
o
a
s
a
e
s		 1
0
9
2
,		 9
6
0		 1
1
%

Fresenius Kabi: Strong Organic Sales Growth

€
m		 /
Q
1
1
2		 /
Q
1
1
1		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
o
p
e
u
r		 4
8
7		 4
4
9		 8
%
h
N
A
i
t
o
r
m
e
r
c
a		 2
9
2		 2
5
4		 0
1
%
f
A
i
P
i
i
s
a
a
c
c
-		 1
9
9		 1
5
6		 2
0
%
f
/
L
i
A
i
A
i
t
n
m
e
a
r
c
a
r
c
a		 1
1
4		 0
1
1		 %
1
5
T
l
l
t
o
a
s
a
e
s		 0
9
2
1
,		 9
0
6		 %
1
1

Fresenius Kabi: Excellent EBIT Improvement

€
m		 /
Q
1
1
2		 /
Q
1
1
1		 G
h
t
r
o
w
E
u
r
o
p
e
M
i
a
g
n
r		 9
6
1
9
7
%		 9
5
2
1.
2
%		 1
%
h
N
A
i
t
o
r
m
e
r
c
a
M
i
a
g
n
r		 1
1
4
3
9
0
%		 9
6
3
7.
8
%		 1
9
%
f
/
/
f
i
i
i
i
i
i
A
P
L
t
A
A
s
a
a
c
c
a
n
m
e
c
a
c
a
r
r
-
M
i
a
r
g
n		 8
5
1
8.
5
%		 2
4
1
6.
3
%		 3
8
%
d
&
C
C
R
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 3
5
-		 3
6
-		 4
7
%
-
T
l
E
B
I
T
t
o
a		 2
1
5		 1
9
7		 %
9
M
i
a
r
g
n		 1
9
7
%		 2
0
5
%

Fresenius Helios: Strong Sales and EBIT Growth

€
m		 /
Q
1
1
2		 /
Q
1
1
1		 G
h
t
r
o
w
l
l
T
t
o
a
s
a
e
s		 7
1
7		 8
6
4		 %
1
1
E
B
I
T
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
M
i
a
r
g
n		 2
7
1
0.
7
%		 8
5
9
0
%		 2
%
4
A
i
i
i
t
c
q
u
s
o
n
s
(
l
d
)
i
t
i
1
<
c
o
n
s
o
a
o
n
y
r		 4
-
T
l
E
B
I
T
t
o
a		 6
8		 5
8		 1
7
%
M
i
a
r
g
n		 9
%
5		 9
0
%

Fresenius Helios: Performance Indicators

Q
/
1
1
2		 Q
/
1
1
1		 C
h
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
i
i
t-
t
o
s
a
c
e
c
a
e
c
n
c
s
u
r
-		 7
5
5
1
2
4		 6
5
4
5
2
0		 1
5
%
3
%
1
2
0
%
1
f
b
d
N
o
o
e
s
A
l
i
i
t
c
u
e
c
a
r
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 3
2
3
6
0
6
,
1
8,
8
0
4
8
0
2
4,		 2
0
2
1
1
,
1
6,
6
9
0
3,
2
2
4		 %
1
7
1
3
%
0
%
4
2
d
A
i
i
m
s
s
o
n
s
(
)
A
i
i
t
t
t
e
a
e
n
p
a
e
n
c
u
c
r
-		 1
7
7,
1
8
5		 1
6
0,
9
4
7		 1
0
%
2
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 8
1
%		 7
8
%
l
h
f
(
d
)
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
u
e
c
a
r
e
-
2
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
6
2
9
7		 6.
6
2
9
8

1 Dec 31, 2011

3 Excl. 160 forensic beds

2Clinics in Germany

Fresenius Vamed: Sales Growth and EBIT in line with Expectations

€
m		 Q
/
1
1
2		 Q
/
1
1
1		 G
h
t
r
o
w
b
j
i
P
t
o
e
c
s
n
e
s
s
r
u		 7
7		 8
4		 8
%
-
b
S
i
i
e
r
v
c
e
u
s
n
e
s
s		 6
5		 6
5		 6
%
1
T
l
l
t
o
a
s
a
e
s		 1
4
2		 1
4
0		 1
%
l
T
E
B
I
T
t
o
a		 5 5 %
0
M
i
a
r
g
n		 3
5
%		 3
6
%
1
O
d
i
k
t
r
e
r
n
a
e		 1
0
4		 1
2
7		 8
%
1
-
1
O
d
b
k
l
r
e
r
a
c
o
g		 8
7
2		 2
8
4
5		 %
3

Share Information

Share key facts

Number of shares1 163,334,670 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Structure Sponsored Level I ADR

1as of March 31, 2012

Financial Calendar

  • 12.06.2012 Capital Market Day Fresenius Kabi
  • 01.08.2012 Report on 1st half 2012
  • 31.10.2012 Report on 1st 3rd quarter 2012

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.